153 related articles for article (PubMed ID: 12232489)
1. Cytoprotective effect of amifostine in radiation-induced acute mucositis - a retrospective analysis.
Kouvaris J; Kouloulias V; Kokakis J; Matsopoulos G; Balafouta M; Miliadou A; Vlahos L
Onkologie; 2002 Aug; 25(4):364-9. PubMed ID: 12232489
[TBL] [Abstract][Full Text] [Related]
2. Impact on cytoprotective efficacy of intermediate interval between amifostine administration and radiotherapy: a retrospective analysis.
Kouloulias VE; Kouvaris JR; Kokakis JD; Kostakopoulos A; Mallas E; Metafa A; Vlahos LJ
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):1148-56. PubMed ID: 15234050
[TBL] [Abstract][Full Text] [Related]
3. [Cytoprotection with amifostine in radiotherapy or radio-chemotherapy of head and neck tumors].
Altmann S; Hoffmanns H
Strahlenther Onkol; 1999 Nov; 175 Suppl 4():30-3. PubMed ID: 10584138
[TBL] [Abstract][Full Text] [Related]
4. Daily amifostine given concomitantly to chemoradiation in head and neck cancer. A pilot study.
Trog D; Bank P; Wendt TG; Koscielny S; Beleites E
Strahlenther Onkol; 1999 Sep; 175(9):444-9. PubMed ID: 10518978
[TBL] [Abstract][Full Text] [Related]
5. A phase II randomized study of topical intrarectal administration of amifostine for the prevention of acute radiation-induced rectal toxicity.
Kouloulias VE; Kouvaris JR; Pissakas G; Kokakis JD; Antypas C; Mallas E; Matsopoulos G; Michopoulos S; Vosdoganis SP; Kostakopoulos A; Vlahos LJ
Strahlenther Onkol; 2004 Sep; 180(9):557-62. PubMed ID: 15378186
[TBL] [Abstract][Full Text] [Related]
6. A randomized study of very accelerated radiotherapy with and without amifostine in head and neck squamous cell carcinoma.
Bourhis J; De Crevoisier R; Abdulkarim B; Deutsch E; Lusinchi A; Luboinski B; Wibault P; Eschwege F
Int J Radiat Oncol Biol Phys; 2000 Mar; 46(5):1105-8. PubMed ID: 10725619
[TBL] [Abstract][Full Text] [Related]
7. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer.
Brizel DM; Wasserman TH; Henke M; Strnad V; Rudat V; Monnier A; Eschwege F; Zhang J; Russell L; Oster W; Sauer R
J Clin Oncol; 2000 Oct; 18(19):3339-45. PubMed ID: 11013273
[TBL] [Abstract][Full Text] [Related]
8. Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: a randomized placebo-controlled phase III study.
Buentzel J; Micke O; Adamietz IA; Monnier A; Glatzel M; de Vries A
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(3):684-91. PubMed ID: 16243440
[TBL] [Abstract][Full Text] [Related]
9. Amifostine as radioprotective agent for the rectal mucosa during irradiation of pelvic tumors. A phase II randomized study using various toxicity scales and rectosigmoidoscopy.
Kouvaris J; Kouloulias V; Malas E; Antypas C; Kokakis J; Michopoulos S; Matsopoulos G; Vlahos L
Strahlenther Onkol; 2003 Mar; 179(3):167-74. PubMed ID: 12627259
[TBL] [Abstract][Full Text] [Related]
10. Subcutaneous administration of amifostine during fractionated radiotherapy: a randomized phase II study.
Koukourakis MI; Kyrias G; Kakolyris S; Kouroussis C; Frangiadaki C; Giatromanolaki A; Retalis G; Georgoulias V
J Clin Oncol; 2000 Jun; 18(11):2226-33. PubMed ID: 10829042
[TBL] [Abstract][Full Text] [Related]
11. Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer.
Antonadou D; Pepelassi M; Synodinou M; Puglisi M; Throuvalas N
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):739-47. PubMed ID: 11849797
[TBL] [Abstract][Full Text] [Related]
12. Phase II multicenter randomized study of amifostine for prevention of acute radiation rectal toxicity: topical intrarectal versus subcutaneous application.
Kouloulias VE; Kouvaris JR; Pissakas G; Mallas E; Antypas C; Kokakis JD; Matsopoulos G; Michopoulos S; Mystakidou K; Vlahos LJ
Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):486-93. PubMed ID: 15890591
[TBL] [Abstract][Full Text] [Related]
13. The cytoprotective effect of amifostine in acute radiation dermatitis: a retrospective analysis.
Kouvaris J; Kouloulias V; Kokakis J; Matsopoulos G; Myrsini B; Vlahos L
Eur J Dermatol; 2002; 12(5):458-62. PubMed ID: 12370135
[TBL] [Abstract][Full Text] [Related]
14. Intermittent use of amifostine during postoperative radiochemotherapy and acute toxicity in rectal cancer patients.
Dunst J; Semlin S; Pigorsch S; Müller AC; Reese T
Strahlenther Onkol; 2000 Sep; 176(9):416-21. PubMed ID: 11050915
[TBL] [Abstract][Full Text] [Related]
15. Serious adverse effects of amifostine during radiotherapy in head and neck cancer patients.
Rades D; Fehlauer F; Bajrovic A; Mahlmann B; Richter E; Alberti W
Radiother Oncol; 2004 Mar; 70(3):261-4. PubMed ID: 15064010
[TBL] [Abstract][Full Text] [Related]
16. Preclinical modeling of improved amifostine (Ethyol) use in radiation therapy.
Cassatt DR; Fazenbaker CA; Bachy CM; Hanson MS
Semin Radiat Oncol; 2002 Jan; 12(1 Suppl 1):97-102. PubMed ID: 11917293
[TBL] [Abstract][Full Text] [Related]
17. Preventing Radiation-Induced Injury by Topical Application of an Amifostine Metabolite-Loaded Thermogel.
Clémenson C; Liu W; Bricout D; Soyez-Herkert L; Chargari C; Mondini M; Haddad R; Wang-Zhang X; Benel L; Bloy C; Deutsch E
Int J Radiat Oncol Biol Phys; 2019 Aug; 104(5):1141-1152. PubMed ID: 31063799
[TBL] [Abstract][Full Text] [Related]
18. [Side effects of postoperative radiochemotherapy with amifostine versus radiochemotherapy alone in head and neck tumors. Preliminary results of a prospective randomized trial].
Vacha P; Marx M; Engel A; Richter E; Feyerabend T
Strahlenther Onkol; 1999 Nov; 175 Suppl 4():18-22. PubMed ID: 10584135
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of subcutaneous amifostine in minimizing radiation-induced toxicities in patients receiving combined-modality treatment for squamous cell carcinoma of the head and neck.
Law A; Kennedy T; Pellitteri P; Wood C; Christie D; Yumen O
Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1361-8. PubMed ID: 17869022
[TBL] [Abstract][Full Text] [Related]
20. Subcutaneous administration of amifostine (ethyol) is equivalent to intravenous administration in a rat mucositis model.
Cassatt DR; Fazenbaker CA; Kifle G; Bachy CM
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):794-802. PubMed ID: 14529786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
